In contrast with Sanders and other Democrats, Biden has not embraced a key executive authority for driving down the cost of pharmaceuticals developed with federally-funded research, like the coronavirus vaccine that is currently being tested.
The staffers, several of whom work for reps on the subcommittee overseeing pharmaceuticals, met with executives from drug companies Merck and Genentech.
After Rep. Greg Walden, the biggest recipient of pharmaceutical campaign cash in the last election cycle, met with Trump, the president decided to scrap his support for lower drug prices.
The industry-led Partnership for America’s Health Care Future, which has assailed Democratic presidential candidates’ reform plans, is drawing on Democratic firms for assistance.
The leading pharmaceutical lobby gave to numerous Republican groups—and one key Democratic one.
Freshman Rep. Anthony Brindisi (D-N.Y.) is advocating a 10-year exclusivity period for biologic drugs as the Blue Dog PAC takes maxed-out donations from the pharmaceutical industry.
With a clearer picture of how Medicare for All can be financed through reducing military spending, voters can debate the merits of a single-payer system without needing to consider any new taxes.
The 19-member panel that advises the Congressional Budget Office on health policy is flush with health insurance, pharmaceutical, and hospital interests.
Buttigieg’s recent transformation into explicit Medicare for All critic was accompanied by continued donations from pharmaceutical and health insurance interests.
The bill is backed by both Trump and Pelosi, so McConnell is standing in the way of a major bipartisan breakthrough that could lower drug prices for millions of Americans.